MedPath

Retraining of balance, nerve glide exercises, resistance training, and instruction in daily living skills are effective treatments for chemotherapy-induced peripheral neuropathy in cancer survivor

Not yet recruiting
Conditions
Malignant (primary) neoplasm, unspecified,
Registration Number
CTRI/2023/03/050356
Lead Sponsor
AMAR JYOTI INSTITUTE OF PHYSIOTHERAPY
Brief Summary

There is rising prevalence of cancer, many individuals are living with side effects of its treatment, as chemotherapy is the mainline treatment. Few studies have been done to investigate potentially beneficial effects of specific exercise to counteract chemotherapy induced peripheral neuropathy symptoms in cancer survivors. The rehabilitative potential of exercise has been so far less investigated and the results are divergent. The majority of studies are done on non natives of India focusing on one or two protocols only at one time. So there is need to investigate the effect of balance Re-education, neural mobilisation, Resistive and activities of daily living training in chemotherapy induced peripheral neuropathy on cancer survivors.

In this study following procedure will be followed:

1. The purpose and benefit of the research will be explained to the cancersurvivors having Chemotherapy induced peripheral neuropathy

2. Consent for participation in research will be taken from the patients

3. Meeting the inclusion andexclusion criteria

4.Baseline assessment willbe performed

 Patient divided intotwo groups

                                                       

| | |

| --- | --- |

|EXPERIMENTAL GROUP

CONTROL GROUP

|N = 14

N = 14

|Will be given intervention exercises, With proper guidance, counseling and precautions.

Education regarding chemotherapy induced peripheral neuropathy its consequences and role of exercises.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
28
Inclusion Criteria

Age 18-60 years had primary diagnosis of cancer -Given chemotherapeutic regimen for atleast 1 cycle -Both Male and female -All types of cancer -Had a karnofsky performance status ≥ 70 -Should be able to walk 3 meters -Have at least 1 neuropathy symptom according to CIPN assessment tool (CIPNAT).

Exclusion Criteria
  • Hereditary peripheral neuropathy .{ e.g., Charcot-marie-tooth disease} -If they had other chronic neuropathic disease likes Diabetic Neuropathy, Multiple Sclerosis, Neuritis etc.
  • Orthopaedic problem that affect balance (e.g. ACL reconstruction) -Vestibular disorder and visual acuity problem -Chronic inflammatory demyelinating polyneuropathy -Concomitant disease like diabetes, renal insufficiencies -Prior history of alcohol abuse -Lower limb amputee -Use of walking Aid -Treatment with antiepileptic drugs, antidepressants and major analgesics.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Modified total neuropathy score A 6 -item tool that combines patient report of subjective sensory and motor symptoms, deep tendon reflexes, manual muscle testing of distal muscles, pin sensibility, and quantitative vibration thresholds.will be assessed at baseline and after 3 weeks
• 0 -24 points, higher score indicates worse neuropathy.will be assessed at baseline and after 3 weeks
Secondary Outcome Measures
NameTimeMethod
functional independence measureThe test/Questionaire will be assessed at the baseline and at the end of 3 weeks. (Pre and Post)
UNIPEDAL STANCE TEST•Patients were asked to stand barefoot on the limb of their choice, with the other limb raised so that the raised foot was near but not touching the ankle of their stance limb.
timed up and go testThe test/Questionaire will be assessed at the baseline and at the end of 3 weeks. (Pre and Post)

Trial Locations

Locations (1)

JIVISHA ADVANCE MEDICAL CENTER

🇮🇳

West, DELHI, India

JIVISHA ADVANCE MEDICAL CENTER
🇮🇳West, DELHI, India
Dr Ajay Dabas
Principal investigator
9811819057
dabas.ajay131@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.